title: Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.
abstract: Interspecies scaling is used to extrapolate pharmacokinetic parameters from animals to humans, through the application of physiologically based models, by empirical allometric procedures, or using concentration-time transformations. The aim of this study was to compare the accuracies of the last two methods for predicting the pharmacokinetic parameters and concentration-time curves in humans. In the first part of this study, interspecies scaling techniques were applied to a hypothetical drug (extracellular distribution and elimination through glomerular filtration), to examine the influence of various laboratory animals (mouse, rat, cynomolgus monkey and dog) on the parameters predicted for man. The same techniques were also applied to interferon-alpha A, using the literature data for various animal species. The kinetic parameters predicted in man were then compared to the values published for man. Our theoretical example showed that, for allometric scaling, each species has a very different influence on the prediction in human. With the approach using concentration-time transformations, however, each animal species potentially makes a similar contribution to the prediction for man. Based on the pharmacokinetic data published for interferon-alpha A in laboratory animals, allometric equations underestimated the observed values of CL and Vdss in man by 2-3-fold, and the prediction of t1/2 was likely to be unreliable, due to a poor correlation. The use of equivalent time, kallynochron, and apolysichron transformations improved the pharmacokinetic predictions for all three parameters in man. In conclusion, concentration-time transformations make more adequate use of the data available in the different species of laboratory animals, to give better predictions of the pharmacokinetic parameters in man.
authors.affiliation: Hoffmann-LaRoche, Basel, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Lave
authors.forename: B
authors.initials: B
authors.lastname: Levet-Trafit
authors.forename: A H
authors.initials: AH
authors.lastname: Schmitt-Hoffmann
authors.forename: B
authors.initials: B
authors.lastname: Morgenroth
authors.forename: W
authors.initials: W
authors.lastname: Richter
authors.forename: R C
authors.initials: RC
authors.lastname: Chou
mesh_terms: D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D000998:Antiviral Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D002522:Chlorocebus aethiops; D004285:Dogs; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000737:chemistry / Q000493:pharmacokinetics*; D008297:Male; D051379:Mice; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D013045:Species Specificity
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins